NO175641B - - Google Patents
Download PDFInfo
- Publication number
- NO175641B NO175641B NO882207A NO882207A NO175641B NO 175641 B NO175641 B NO 175641B NO 882207 A NO882207 A NO 882207A NO 882207 A NO882207 A NO 882207A NO 175641 B NO175641 B NO 175641B
- Authority
- NO
- Norway
- Prior art keywords
- insulin
- physiologically acceptable
- des
- human
- component
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 96
- 102000004877 Insulin Human genes 0.000 claims abstract description 45
- 108090001061 Insulin Proteins 0.000 claims abstract description 44
- 239000013078 crystal Substances 0.000 claims abstract description 43
- 229940125396 insulin Drugs 0.000 claims abstract description 43
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims abstract description 14
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims abstract description 13
- 238000002425 crystallisation Methods 0.000 claims abstract description 8
- 230000008025 crystallization Effects 0.000 claims abstract description 8
- 108700007397 Arg(B31)- insulin Proteins 0.000 claims abstract description 5
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000007951 isotonicity adjuster Substances 0.000 claims description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 7
- 210000004899 c-terminal region Anatomy 0.000 abstract description 6
- 235000015278 beef Nutrition 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 235000015277 pork Nutrition 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 12
- 239000011701 zinc Substances 0.000 description 11
- 239000004026 insulin derivative Substances 0.000 description 9
- 229910052725 zinc Inorganic materials 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 102000007327 Protamines Human genes 0.000 description 5
- 108010007568 Protamines Proteins 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940048914 protamine Drugs 0.000 description 5
- 108010005991 Pork Regular Insulin Proteins 0.000 description 4
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 101001011741 Bos taurus Insulin Proteins 0.000 description 3
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 3
- 108700025974 depot- insulin Proteins 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 101150026173 ARG2 gene Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- -1 aromatic hydroxy compounds Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101000993800 Sus scrofa Insulin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19873717370 DE3717370A1 (de) | 1987-05-22 | 1987-05-22 | Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus |
Publications (4)
Publication Number | Publication Date |
---|---|
NO882207D0 NO882207D0 (no) | 1988-05-20 |
NO882207L NO882207L (no) | 1988-11-23 |
NO175641B true NO175641B (fr) | 1994-08-01 |
NO175641C NO175641C (no) | 1994-11-09 |
Family
ID=6328227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO882207A NO175641C (no) | 1987-05-22 | 1988-05-20 | Fremgangsmåte for fremstilling av blandingskrystaller av insulin og insulinderivater |
Country Status (20)
Country | Link |
---|---|
US (1) | US5028587A (fr) |
EP (1) | EP0291863B1 (fr) |
JP (1) | JPS63303930A (fr) |
KR (1) | KR880013572A (fr) |
AT (1) | ATE71842T1 (fr) |
AU (1) | AU601280B2 (fr) |
CA (1) | CA1335924C (fr) |
DE (2) | DE3717370A1 (fr) |
DK (1) | DK278088A (fr) |
ES (1) | ES2032896T3 (fr) |
FI (1) | FI93797C (fr) |
GR (1) | GR3004344T3 (fr) |
HU (1) | HU203840B (fr) |
IE (1) | IE60649B1 (fr) |
IL (1) | IL86452A (fr) |
NO (1) | NO175641C (fr) |
NZ (1) | NZ224715A (fr) |
PH (1) | PH25587A (fr) |
PT (1) | PT87523B (fr) |
ZA (1) | ZA883599B (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK134189D0 (da) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
WO1992010284A2 (fr) | 1990-12-07 | 1992-06-25 | Cnc Development, Inc. | Reacteur chimique catalytique |
AU669110B2 (en) * | 1991-05-24 | 1996-05-30 | Amylin Pharmaceuticals, Inc. | Amylin and possibly insulin containing composition for the treatment of anorexia and related states |
DK72793D0 (da) * | 1993-06-21 | 1993-06-21 | Novo Nordisk As | Nyt produkt |
US5461031A (en) * | 1994-06-16 | 1995-10-24 | Eli Lilly And Company | Monomeric insulin analog formulations |
US5504188A (en) * | 1994-06-16 | 1996-04-02 | Eli Lilly And Company | Preparation of stable zinc insulin analog crystals |
US5474978A (en) * | 1994-06-16 | 1995-12-12 | Eli Lilly And Company | Insulin analog formulations |
US5547929A (en) * | 1994-09-12 | 1996-08-20 | Eli Lilly And Company | Insulin analog formulations |
US5597893A (en) * | 1994-10-31 | 1997-01-28 | Eli Lilly And Company | Preparation of stable insulin analog crystals |
US6004549A (en) * | 1994-12-14 | 1999-12-21 | Schering Corporation | Crystalline protein controlled release compositions |
CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
DE19903125B4 (de) * | 1999-01-27 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga |
CN1125081C (zh) * | 1999-09-08 | 2003-10-22 | 中国科学院上海生物化学研究所 | 重组天然和新型人胰岛素及其制备方法 |
NZ526672A (en) * | 2001-02-09 | 2006-10-27 | Genentech Inc | Process for forming crystalline human insulin-like growth factor-1 |
US7396936B1 (en) | 2004-11-09 | 2008-07-08 | Kemia, Inc. | Modulators of calcitonin and amylin receptor activity |
JP2010510988A (ja) * | 2006-11-28 | 2010-04-08 | マリナス ファーマシューティカルズ | ナノ粒子製剤とその製造方法およびその利用 |
US9822158B2 (en) | 2013-12-04 | 2017-11-21 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
EP3185887B1 (fr) | 2014-08-26 | 2021-03-10 | Merck Sharp & Dohme Corp. | Procédé de préparation de compositions d'analogue d'insuline ou d'insuline cristallines |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2538018A (en) * | 1944-04-04 | 1951-01-16 | Nordisk Insulinlab | Crystalline product of insulin and alkaline protein and process of making it |
EG12098A (en) * | 1974-04-13 | 1980-12-31 | Hoechst Ag | New pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture |
DE3326472A1 (de) * | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
DE3326473A1 (de) * | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
DE3333640A1 (de) * | 1983-09-17 | 1985-04-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung |
-
1987
- 1987-05-22 DE DE19873717370 patent/DE3717370A1/de not_active Withdrawn
-
1988
- 1988-05-13 ES ES198888107667T patent/ES2032896T3/es not_active Expired - Lifetime
- 1988-05-13 AT AT88107667T patent/ATE71842T1/de not_active IP Right Cessation
- 1988-05-13 DE DE8888107667T patent/DE3867903D1/de not_active Expired - Fee Related
- 1988-05-13 EP EP88107667A patent/EP0291863B1/fr not_active Expired - Lifetime
- 1988-05-19 PT PT87523A patent/PT87523B/pt not_active IP Right Cessation
- 1988-05-19 FI FI882354A patent/FI93797C/fi not_active IP Right Cessation
- 1988-05-20 PH PH36954A patent/PH25587A/en unknown
- 1988-05-20 NZ NZ224715A patent/NZ224715A/en unknown
- 1988-05-20 IL IL86452A patent/IL86452A/xx unknown
- 1988-05-20 IE IE152288A patent/IE60649B1/en not_active IP Right Cessation
- 1988-05-20 NO NO882207A patent/NO175641C/no unknown
- 1988-05-20 ZA ZA883599A patent/ZA883599B/xx unknown
- 1988-05-20 US US07/196,530 patent/US5028587A/en not_active Expired - Fee Related
- 1988-05-20 CA CA000567377A patent/CA1335924C/fr not_active Expired - Fee Related
- 1988-05-20 KR KR1019880005946A patent/KR880013572A/ko not_active Application Discontinuation
- 1988-05-20 AU AU16487/88A patent/AU601280B2/en not_active Ceased
- 1988-05-20 JP JP63122211A patent/JPS63303930A/ja active Pending
- 1988-05-20 HU HU882597A patent/HU203840B/hu not_active IP Right Cessation
- 1988-05-20 DK DK278088A patent/DK278088A/da not_active Application Discontinuation
-
1992
- 1992-04-15 GR GR920400389T patent/GR3004344T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
ATE71842T1 (de) | 1992-02-15 |
EP0291863A2 (fr) | 1988-11-23 |
DE3867903D1 (de) | 1992-03-05 |
DK278088A (da) | 1988-11-23 |
IL86452A0 (en) | 1988-11-15 |
HUT46546A (en) | 1988-11-28 |
PH25587A (en) | 1991-08-08 |
AU601280B2 (en) | 1990-09-06 |
NO882207D0 (no) | 1988-05-20 |
NO882207L (no) | 1988-11-23 |
NO175641C (no) | 1994-11-09 |
DE3717370A1 (de) | 1988-12-01 |
IL86452A (en) | 1993-02-21 |
ZA883599B (en) | 1989-01-25 |
JPS63303930A (ja) | 1988-12-12 |
HU203840B (en) | 1991-10-28 |
AU1648788A (en) | 1988-11-24 |
ES2032896T3 (es) | 1993-03-01 |
FI93797C (fi) | 1995-06-12 |
NZ224715A (en) | 1990-04-26 |
FI882354A (fi) | 1988-11-23 |
EP0291863A3 (en) | 1990-04-04 |
US5028587A (en) | 1991-07-02 |
GR3004344T3 (fr) | 1993-03-31 |
FI882354A0 (fi) | 1988-05-19 |
IE60649B1 (en) | 1994-08-10 |
PT87523A (pt) | 1989-05-31 |
IE881522L (en) | 1988-11-22 |
KR880013572A (ko) | 1988-12-21 |
EP0291863B1 (fr) | 1992-01-22 |
DK278088D0 (da) | 1988-05-20 |
FI93797B (fi) | 1995-02-28 |
PT87523B (pt) | 1992-09-30 |
CA1335924C (fr) | 1995-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO175641B (fr) | ||
FI79786C (fi) | Foerfarande foer framstaellning ett farmaceutiskt medel foer behandling av diabetes. | |
DE69737479T2 (de) | Glp-1 derivate | |
NO178914B (no) | Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av Diabetes mellitus | |
DE69529708T2 (de) | Herstellung von stabilen Zink-Insulinanalogen-Kristallen | |
Sayers et al. | The cholesterol and ascorbic acid content of the adrenal, liver, brain, and plasma following hemorrhage | |
KR100386038B1 (ko) | 단량체성인슐린유사체의제제 | |
US7226990B2 (en) | Extendin derivatives | |
EP1161452B1 (fr) | Dimeres d'insuline pontes de maniere covalente | |
HU201475B (en) | Process for producing liquide insulin compositions | |
NZ246556A (en) | Pharmaceutical composition of a growth hormone and histidine | |
EP0119650A2 (fr) | Conjugués de galactosyl-insuline utilisés dans le traitement des diabétiques | |
DE69525955T2 (de) | Ein wachstumshormon und isoleucin enthaltende pharmazeutische formulierung | |
Eigenmann et al. | Decrease of non-suppressible insulin-like activity after pancreatectomy and normalization by insulin therapy | |
US8927489B2 (en) | Sustained release preparation of pro-insulin C-peptide | |
KR20200038502A (ko) | 신규한 아실화 인슐린 유사체 및 이의 용도 | |
DE69935296T2 (de) | IP3 bindendes Polypeptid mit hoher Affinität | |
Bollman et al. | Action of glucose and insulin on free amino acids of the dehepatized dog | |
CN115337391A (zh) | 胰岛素化合物与glp-1受体激动剂的复方制剂及其医药用途 | |
Segal | Insulin inhibition and antagonism | |
JP3260760B2 (ja) | ヒルジンを含んでなる医薬組成物 | |
Trading et al. | Biological and chemical properties of two glucagon preparations with prolonged action | |
JPH0859506A (ja) | 修飾型アンチトロンビン含有製剤 | |
CH646414A5 (en) | Purified pancreatic spasmolytic polypeptide, process for its isolation, and pharmaceutical composition |